Maze appoints ex-Incyte CEO Hervé Hoppenot as Chairman, effective Oct 6

Maze Therapeutics, Inc.

Hervé Hoppenot appointed Class II director and Chairman of the Board, succeeding Charles Homcy, who remains a director.
Hoppenot served as Incyte CEO (2014-2025) and Chairman (2015-2025); also on boards of Bicycle Therapeutics and Laboratoires Pierre Fabre.
Receives pro rata portions of $40k director retainer and $30k Chairman retainer; granted option for 36,000 shares vesting over 36 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.